Is Nephro Care overvalued or undervalued?

As of 9 September 2025, the valuation grade for Nephro Care has moved from expensive to very expensive, indicating a significant increase in perceived overvaluation. The company is currently assessed as overvalued. Key ratios include a PE ratio of 77.45, an EV to EBITDA of 44.51, and a price to book value of 5.27, all of which are considerably high compared to industry norms.
In comparison to peers, Apollo Hospitals is rated attractive with a PE of 71.64 and an EV to EBITDA of 36.83, while Max Healthcare is very expensive with a PE of 93.08 and an EV to EBITDA of 57.68. Nephro Care's high ratios suggest it is trading at a premium relative to its competitors, reinforcing the conclusion of overvaluation. Additionally, the recent stock performance shows a decline of 36.54% over the past year, contrasting with a slight gain of 0.27% in the Sensex, further highlighting the challenges faced by the company in the current market environment.